Results 51 to 60 of about 104,915 (286)

Experience and lessons learned relating to investigational product supply in the design and delivery of a paediatric investigator-initiated clinical trial

Contemporary Clinical Trials Communications
The management of investigational product (IP) supply is a complex endeavour when designing and delivering clinical trials. In contrast to industry-sponsored trials where IP supplies are coordinated by teams of specialists working together throughout the
Mandy Wan, Mark A. Turner, Gilles Cambonie, Ruth Kemper, Naouel Bouafia, Lea Levoyer, Alpha Diallo, Mikko Hallman, Jean-Christophe Rozé   +8 more
doaj   +1 more source

Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use. A systematic review [PDF]

, 2017
A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted.
Cohen, Joel L, Scuderi, Nicolo'
core   +1 more source

Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani, Lakshmi Pillai, Reid D. Landes, Aliyah Glover, Shannon Doerhoff, Jennifer Kleiner, Mitesh Lotia, Rohit Dhall, Edgar Garcia‐Rill   +8 more
wiley   +1 more source

Benefit assessment of extended dosing in cancer patients after their withdrawal from clinical trials

Frontiers in Pharmacology, 2023
Background: Clinical trials have been widely recognized as an effective treatment approach by physicians and cancer patients alike. Physicians’ evaluations suggest that many patients are likely to continue experiencing benefits from extended dosing of ...
Feng Yang, Zhe Huang, Zhe Huang, Jianfu Heng, Kunyan Li   +4 more
doaj   +1 more source

Stem cell clinical trials [PDF]

, 2013
No description ...
Rosemann, Achim
core  

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen, Ceren Tozlu, Tina Roostaei, Fatoumata Diallo, Kaho Onomichi, Jiyeon Son, Zongqi Xia, Philip L. De Jager   +7 more
wiley   +1 more source

Enhancing Clinical Trials Through Synergistic Gamma Power Analysis

Frontiers in Psychiatry, 2020
While the etiology of many neuropsychiatric disorders remains unknown, increasing evidence suggests that aberrant sensory processing plays a central role.
Sokichi Honda, Mitsuyuki Matsumoto, Katsunori Tajinda, Takuma Mihara   +3 more
doaj   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Criteria for the use of omics-based predictors in clinical trials. [PDF]

, 2013
The US National Cancer Institute (NCI), in collaboration with scientists representing multiple areas of expertise relevant to 'omics'-based test development, has developed a checklist of criteria that can be used to determine the readiness of omics-based
A Dupuy, AM Molinaro, B Freidlin, Barbara A. Conley, David A. Eberhard, Deborah J. Shuman, HM Moore, J Subramanian, James H. Doroshow, James V. Tricoli, Jeremy M. G. Taylor, Jill P. Mesirov, JT Leek, Kelly Y. Kim, KK Dobbin, L Shi, Lisa M. McShane, LM McShane, Margaret M. Cavenagh, Mei-Yin C. Polley, P. Mickey Williams, R Simon, Richard M. Simon, RM Simon, Tracy G. Lively, William L. Bigbee   +25 more
core   +2 more sources

Promising treatments of tomorrow for multiple sclerosis

Annals of Indian Academy of Neurology, 2009
The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development.
Harrison Daniel, Calabresi Peter
doaj